FDA Mulls Testosterone Boost for Men's Flagging Sex Drives
Published Date: 4/20/2026
Notice
Summary
The FDA is exploring a new use for testosterone replacement therapy (TRT) to help men with low sex drive caused by idiopathic hypogonadism. Drug makers with approved TRT products are invited to apply for this new treatment option by April 30, 2026. This could mean more treatment choices for men and new business opportunities for companies.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Possible New TRT Treatment Option
You may have more treatment choices: FDA's preliminary review of published trials suggests testosterone replacement therapy (TRT) may be safe and effective for treating low sex drive in men with decreased libido associated with idiopathic hypogonadism. FDA says holders of approved TRT drugs should contact the agency by April 30, 2026 about submitting a supplemental NDA to seek approval for this use.
Business Opportunity for TRT Manufacturers
Drug makers that already have FDA-approved TRT products are invited to seek a new indication and should contact FDA by April 30, 2026 for details on submitting a supplemental NDA. The notice also states that patent protections and regulatory exclusivities may affect the timing of approvals for subsequent applicants.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in